

Joanne Edwards

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5837875/publications.pdf>

Version: 2024-02-01

191
papers

10,095
citations

36303

51
h-index

40979

93
g-index

198
all docs

198
docs citations

198
times ranked

15627
citing authors

#	ARTICLE	IF	CITATIONS
1	THYM6-mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. <i>EMBO Molecular Medicine</i> , 2022, 14, e14764.	6.9	12
2	Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer. <i>British Journal of Cancer</i> , 2022, , .	6.4	2
3	Molecular mechanisms of tumour budding and its association with microenvironment in colorectal cancer. <i>Clinical Science</i> , 2022, 136, 521-535.	4.3	4
4	The relationship between the Glasgow Microenvironment Score and markers of epithelial-mesenchymal transition in TNM II-III colorectal cancer. <i>Human Pathology</i> , 2022, 127, 1-11.	2.0	2
5	The Relationship Between the Tumor Cell Expression of Hypoxic Markers and Survival in Patients With ER-positive Invasive Ductal Breast Cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2022, 70, 479-494.	2.5	4
6	The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. <i>British Journal of Cancer</i> , 2021, 124, 786-796.	6.4	11
7	The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress. <i>Cell Death and Differentiation</i> , 2021, 28, 1563-1578.	11.2	19
8	MNK Inhibition Sensitizes <i>KRAS</i> -Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression. <i>Cancer Discovery</i> , 2021, 11, 1228-1247.	9.4	45
9	Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 121-134.	3.0	17
10	The relationship between hypoxia-inducible factor 1 \pm (HIF-1 \pm) and patient survival in breast cancer: Systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103231.	4.4	20
11	The inflammatory microenvironment in screen-detected premalignant adenomatous polyps: early results from the integrated technologies for improved polyp surveillance (INCISE) project. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 983-989.	1.6	3
12	MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer. <i>Cell Death and Differentiation</i> , 2021, 28, 2970-2982.	11.2	13
13	The relationship between β -catenin and patient survival in colorectal cancer systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103337.	4.4	8
14	Novel Methods of Risk Stratifying Patients for Metachronous, Pre-Malignant Colorectal Polyps: A Systematic Review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 164, 103421.	4.4	5
15	Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). <i>Radiation Oncology</i> , 2021, 16, 163.	2.7	9
16	Systematic review of tumour budding and association with common mutations in patients with colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 167, 103490.	4.4	3
17	Preoperative, biopsy-based assessment of the tumour microenvironment in patients with primary operable colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 30-39.	3.0	11
18	Activation of β -Catenin Cooperates with Loss of Pten to Drive AR-Independent Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 576-590.	0.9	26

#	ARTICLE	IF	CITATIONS
19	BRF1 accelerates prostate tumorigenesis and perturbs immune infiltration. <i>Oncogene</i> , 2020, 39, 1797-1806.	5.9	10
20	High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro. <i>Biomolecules</i> , 2020, 10, 1365.	4.0	22
21	The effect of postoperative complications on survival and recurrence after surgery for breast cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 155, 103075.	4.4	13
22	Determining the prognostic significance of IKK ζ in prostate cancer. <i>Prostate</i> , 2020, 80, 1188-1202.	2.3	5
23	Gut $\gamma\delta$ T cells as guardians, disruptors, and instigators of cancer. <i>Immunological Reviews</i> , 2020, 298, 198-217.	6.0	28
24	Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naïve prostate cancer. <i>Prostate</i> , 2020, 80, 1353-1364.	2.3	4
25	Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 596-606.	3.9	7
26	Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 283-296.	3.0	17
27	RUNX1 Is a Driver of Renal Cell Carcinoma Correlating with Clinical Outcome. <i>Cancer Research</i> , 2020, 80, 2325-2339.	0.9	21
28	Local immune response in colon cancer: Indicative of good or poor prognosis?. <i>Journal of Clinical Oncology</i> , 2020, 38, 213-213.	1.6	0
29	The relationship between members of the canonical NF- κ B pathway, tumour microenvironment and cancer specific survival in colorectal cancer patients. <i>Histology and Histopathology</i> , 2020, 35, 569-578.	0.7	1
30	The role of gamma delta T lymphocytes in breast cancer: a review. <i>Translational Research</i> , 2019, 203, 88-96.	5.0	46
31	A novel tumor-based epithelial-mesenchymal transition score that associates with prognosis and metastasis in patients with Stage II/III colorectal cancer. <i>International Journal of Cancer</i> , 2019, 144, 150-159.	5.1	28
32	The Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in Patients with Primary Operable Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 4397-4404.	1.5	47
33	Src family kinases, HCK and FGR, associate with local inflammation and tumour progression in colorectal cancer. <i>Cellular Signalling</i> , 2019, 56, 15-22.	3.6	38
34	Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. <i>Clinical Science</i> , 2019, 133, 181-193.	4.3	51
35	The relationship between phosphorylation status of focal adhesion kinases, molecular subtypes, tumour microenvironment and survival in patients with primary operable ductal breast cancer. <i>Cellular Signalling</i> , 2019, 60, 91-99.	3.6	7
36	A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer. <i>Translational Research</i> , 2019, 206, 91-106.	5.0	20

#	ARTICLE	IF	CITATIONS
37	Signal interaction between the tumour and inflammatory cells in patients with gastrointestinal cancer: Implications for treatment. <i>Cellular Signalling</i> , 2019, 54, 81-90.	3.6	11
38	The association between markers of tumour cell metabolism, the tumour microenvironment and outcomes in patients with colorectal cancer. <i>International Journal of Cancer</i> , 2019, 144, 2320-2329.	5.1	10
39	The NF-KB pathway and endocrine therapy resistance in breast cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, R369-R380.	3.1	85
40	The relationship between tumor budding, tumor microenvironment, and survival in patients with primary operable colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 581-581.	1.6	1
41	Comorbidity and systemic inflammation are independent prognostic factors in patients with colorectal cancer: A ScotScan collaborative study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 707-707.	1.6	0
42	The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer. <i>British Journal of Cancer</i> , 2018, 118, 705-712.	6.4	46
43	MCL-1 is a prognostic indicator and drug target in breast cancer. <i>Cell Death and Disease</i> , 2018, 9, 19.	6.3	134
44	Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial. <i>Journal of the National Cancer Institute</i> , 2018, 110, 616-627.	6.3	8
45	Sprouty2 loss-induced IL 6 drives castration-resistant prostate cancer through scavenger receptor B1. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	19
46	NF- κ B pathways in the development and progression of colorectal cancer. <i>Translational Research</i> , 2018, 197, 43-56.	5.0	164
47	Mannose impairs tumour growth and enhances chemotherapy. <i>Nature</i> , 2018, 563, 719-723.	27.8	282
48	Drug screening of biopsy-derived spheroids using a self-generated microfluidic concentration gradient. <i>Scientific Reports</i> , 2018, 8, 14672.	3.3	93
49	Reply to comment of "ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer"; <i>British Journal of Cancer</i> , 2018, 119, 909-909.	6.4	0
50	Inhibitory- κ B Kinase (IKK) \pm and Nuclear Factor- κ B (NF- κ B)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets. <i>Cells</i> , 2018, 7, 176.	4.1	49
51	ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 323-329.	6.4	11
52	Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12. <i>Oncogene</i> , 2018, 37, 4679-4691.	5.9	31
53	The Prognostic Role of the Non-Canonical Nuclear Factor-Kappa B Pathway in Renal Cell Carcinoma Patients. <i>Urologia Internationalis</i> , 2018, 101, 190-196.	1.3	9
54	A proteomic approach to identify endosomal cargoes controlling cancer invasiveness. <i>Journal of Cell Science</i> , 2017, 130, 697-711.	2.0	19

#	ARTICLE	IF	CITATIONS
55	In reply to Hynes et al. Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study TM . <i>Histopathology</i> , 2017, 71, 326-327.	2.9	2
56	Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer. <i>British Journal of Cancer</i> , 2017, 116, 1444-1450.	6.4	46
57	Colorectal cancer subtypes: Translation to routine clinical pathology. <i>Cancer Treatment Reviews</i> , 2017, 57, 1-7.	7.7	36
58	High IKK \pm expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER) α -positive breast cancer. <i>International Journal of Cancer</i> , 2017, 140, 1633-1644.	5.1	22
59	The relationship between oestrogen receptor α phosphorylation and the tumour microenvironment in patients with primary operable ductal breast cancer. <i>Histopathology</i> , 2017, 70, 782-797.	2.9	2
60	Inhibitory Kappa B Kinase \pm (IKK \pm) Inhibitors That Recapitulate Their Selectivity in Cells against Isoform-Related Biomarkers. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7043-7066.	6.4	23
61	Signal Transduction and Activator of Transcription-3 (STAT3) in Patients with Colorectal Cancer: Associations with the Phenotypic Features of the Tumor and Host. <i>Clinical Cancer Research</i> , 2017, 23, 1698-1709.	7.0	38
62	The Pretreatment Systemic Inflammatory Response is an Important Determinant of Poor Pathologic Response for Patients Undergoing Neoadjuvant Therapy for Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 1295-1303.	1.5	34
63	Androgen receptor phosphorylation status at serine 578 predicts poor outcome in prostate cancer patients. <i>Oncotarget</i> , 2017, 8, 4875-4887.	1.8	14
64	The relationship between members of the canonical NF- κ B pathway, components of tumour microenvironment and survival in patients with invasive ductal breast cancer. <i>Oncotarget</i> , 2017, 8, 33002-33013.	1.8	15
65	Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 37172-37185.	1.8	6
66	Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 8290-8295.	7.1	91
67	Comparison of the prognostic value of measures of the tumor inflammatory cell infiltrate and tumor-associated stroma in patients with primary operable colorectal cancer. <i>Oncolmmunology</i> , 2016, 5, e1098801.	4.6	29
68	The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone. <i>British Journal of Cancer</i> , 2016, 115, 967-973.	6.4	26
69	Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients. <i>BMC Cancer</i> , 2016, 16, 229.	2.6	30
70	The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer. <i>British Journal of Cancer</i> , 2016, 115, 156-163.	6.4	54
71	Loss of signal transducer and activator of transcription 1 is associated with prostate cancer recurrence. <i>Molecular Carcinogenesis</i> , 2016, 55, 1667-1677.	2.7	12
72	Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment. <i>British Journal of Cancer</i> , 2016, 114, 562-570.	6.4	59

#	ARTICLE	IF	CITATIONS
73	Relationship between tumour PTEN/Akt/COX-2 expression, inflammatory response and survival in patients with colorectal cancer. <i>Oncotarget</i> , 2016, 7, 70601-70612.	1.8	12
74	The relationship between total and phosphorylated STAT1 and STAT3 tumour cell expression, components of tumour microenvironment and survival in patients with invasive ductal breast cancer. <i>Oncotarget</i> , 2016, 7, 77607-77621.	1.8	16
75	Signal transduction and activator of transcription 3 (STAT3), host inflammatory responses and survival of patients with colorectal cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 606-606.	1.6	1
76	Elevated LIM Kinase 1 in Nonmetastatic Prostate Cancer Reflects Its Role in Facilitating Androgen Receptor Nuclear Translocation. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 246-258.	4.1	30
77	The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer. <i>British Journal of Cancer</i> , 2015, 113, 1066-1074.	6.4	67
78	Evaluation of a Tumor Microenvironmentâ€Based Prognostic Score in Primary Operable Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 882-888.	7.0	69
79	Expression of RUNX1 Correlates with Poor Patient Prognosis in Triple Negative Breast Cancer. <i>PLoS ONE</i> , 2014, 9, e100759.	2.5	80
80	Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer. <i>BMC Cancer</i> , 2014, 14, 676.	2.6	41
81	CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer. <i>Journal of Cell Science</i> , 2014, 127, 3893-901.	2.0	85
82	RUNX2 in subtype specific breast cancer and mammary gland differentiation. <i>DMM Disease Models and Mechanisms</i> , 2014, 7, 525-34.	2.4	53
83	SIRT2: Tumour suppressor or tumour promoter in operable breast cancer?. <i>European Journal of Cancer</i> , 2014, 50, 290-301.	2.8	78
84	The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer. <i>British Journal of Cancer</i> , 2014, 111, 157-165.	6.4	90
85	The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 231-241.	4.4	63
86	Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy. <i>European Urology</i> , 2014, 66, 32-39.	1.9	139
87	Abstract 976: Junctional adhesion molecule-A (JAM-A) expression is downmodulated by miR-21 during colorectal cancer progression. , 2014, , .		0
88	Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1â€phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptorâ€positive breast cancer. <i>International Journal of Cancer</i> , 2013, 132, 605-616.	5.1	40
89	Activation of the IL-6R/Jak/Stat Pathway is Associated with a Poor Outcome in Resected Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 887-898.	1.7	80
90	IGFBP-5 enhances epithelial cell adhesion and protects epithelial cells from TGFÎ²1-induced mesenchymal invasion. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 2774-2785.	2.8	26

#	ARTICLE	IF	CITATIONS
91	Senescent cells harbour features of the cancer epigenome. <i>Nature Cell Biology</i> , 2013, 15, 1495-1506.	10.3	300
92	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R92.	5.0	320
93	Reclassification of the Fuhrman grading system in renal cell carcinoma-does it make a difference?. <i>SpringerPlus</i> , 2013, 2, 378.	1.2	6
94	The relationship between genetic profiling, clinicopathological factors and survival in patients undergoing surgery for node-negative colorectal cancer: 10-year follow-up. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 2013-2020.	2.5	3
95	Interactions between MAP kinase and oestrogen receptor in human breast cancer. <i>European Journal of Cancer</i> , 2013, 49, 1176-1186.	2.8	15
96	Pathological Correlation between Number of Biopsies and Radical Surgery: Does It Make a Difference to Final Pathology?. <i>Current Urology</i> , 2013, 7, 24-27.	0.6	0
97	Comparison of visual and automated assessment of microvessel density and their impact on outcome in primary operable invasive ductal breast cancer. <i>Human Pathology</i> , 2013, 44, 1688-1695.	2.0	12
98	A Prospective Study of the Role of Inflammation in Bladder Cancer. <i>Current Urology</i> , 2013, 6, 189-193.	0.6	16
99	The Epidemiology and Risk Factors for Renal Cancer. <i>Current Urology</i> , 2013, 6, 169-174.	0.6	26
100	The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancer. <i>BMC Clinical Pathology</i> , 2013, 13, 31.	1.8	37
101	Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients. <i>British Journal of Cancer</i> , 2013, 108, 139-148.	6.4	52
102	Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2013, 14, 16656-16671.	4.1	13
103	Body Mass Index Predicts Failure of Surgical Management in Benign Prostatic Hyperplasia. <i>Urologia Internationalis</i> , 2013, 90, 150-155.	1.3	8
104	The Prognostic Use of Inflammation and Tissue Necrosis in Benign Prostatic Hyperplasia. <i>Urologia Internationalis</i> , 2013, 91, 19-25.	1.3	6
105	The in situ local immune response, tumour senescence and proliferation in colorectal cancer. <i>British Journal of Cancer</i> , 2013, 109, 2207-2216.	6.4	23
106	The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. <i>British Journal of Cancer</i> , 2013, 109, 1676-1684.	6.4	124
107	Regulation of cell survival by sphingosine-1-phosphate receptor S1P1 via reciprocal ERK-dependent suppression of Bim and PI-3-kinase/protein kinase C-mediated upregulation of Mcl-1. <i>Cell Death and Disease</i> , 2013, 4, e927-e927.	6.3	74
108	Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. <i>Journal of Clinical Investigation</i> , 2013, 123, 1157-1175.	8.2	75

#	ARTICLE	IF	CITATIONS
109	Association of the canonical NF- κ B pathway with clinical outcome measures in ER-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 588-588.	1.6	0
110	The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. <i>British Journal of Cancer</i> , 2012, 107, 864-873.	6.4	132
111	Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. <i>British Journal of Cancer</i> , 2012, 106, 1453-1459.	6.4	59
112	NF κ B signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression. <i>British Journal of Cancer</i> , 2012, 107, 1554-1563.	6.4	55
113	Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. <i>British Journal of Cancer</i> , 2012, 106, 383-388.	6.4	78
114	The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder. <i>British Journal of Cancer</i> , 2012, 106, 1187-1195.	6.4	17
115	The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma. <i>British Journal of Cancer</i> , 2012, 106, 702-710.	6.4	40
116	Expression and prognostic significance of Src family members in renal clear cell carcinoma. <i>British Journal of Cancer</i> , 2012, 107, 856-863.	6.4	30
117	Prospective Study of the Role of Inflammation in Renal Cancer. <i>Urologia Internationalis</i> , 2012, 88, 277-281.	1.3	29
118	Is the Presence or Absence of Tumour Necrosis a Significant Predictor of Survival in Renal Cell Cancer?. <i>Urologia Internationalis</i> , 2012, 88, 79-83.	1.3	2
119	Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers. <i>Frontiers in Oncology</i> , 2012, 2, 168.	2.8	37
120	The Histone Deacetylase SIRT6 Is a Tumor Suppressor that Controls Cancer Metabolism. <i>Cell</i> , 2012, 151, 1185-1199.	28.9	561
121	Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2012, 72, 3457-3462.	0.9	518
122	Targeting sphingosine kinase 1 in cancer. <i>Advances in Biological Regulation</i> , 2012, 52, 31-38.	2.3	37
123	The relationship between tumour site, clinicopathological characteristics and cancer-specific survival in patients undergoing surgery for colorectal cancer. <i>Colorectal Disease</i> , 2012, 14, 1493-1499.	1.4	52
124	Nuclear factor κ B predicts poor outcome in patients with hormone-naïve prostate cancer with high nuclear androgen receptor. <i>Human Pathology</i> , 2012, 43, 1491-1500.	2.0	16
125	The role of the tumour inflammatory cell infiltrate in predicting recurrence and survival in patients with primary operable breast cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 943-955.	7.7	40
126	Sphingosine 1-phosphate signalling in cancer. <i>Biochemical Society Transactions</i> , 2012, 40, 94-100.	3.4	109

#	ARTICLE	IF	CITATIONS
127	Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer. <i>Cancer Biomarkers</i> , 2012, 10, 91-99.	1.7	11
128	SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis. <i>EMBO Molecular Medicine</i> , 2012, 4, 776-790.	6.9	46
129	The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 723-728.	2.5	22
130	Breast cancer outcomes by steroid hormone receptor status assessed visually and by computer image analysis. <i>Histopathology</i> , 2012, 61, 283-292.	2.9	26
131	Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer. <i>Histopathology</i> , 2012, 61, 675-684.	2.9	25
132	Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 327-332.	2.5	13
133	Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. <i>British Journal of Cancer</i> , 2011, 104, 1920-1928.	6.4	70
134	Expression of hypoxia inducible factor-1 alpha in matched hormone naive and castrate resistant prostate cancer specimens. <i>Cancer Biomarkers</i> , 2011, 8, 1-9.	1.7	2
135	Interrelationships between Tumor Proliferative Activity, Leucocyte and Macrophage Infiltration, Systemic Inflammatory Response, and Survival in Patients Selected for Potentially Curative Resection for Gastroesophageal Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 2604-2612.	1.5	22
136	GRP78 up-regulation is associated with androgen receptor status, Hsp70 and Hsp90 client proteins and castrate-resistant prostate cancer. <i>Journal of Pathology</i> , 2011, 223, 81-87.	4.5	53
137	Heregulin Expression and Prognosis in Prostate Adenocarcinoma. <i>Urologia Internationalis</i> , 2011, 87, 363-368.	1.3	4
138	HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 16392-16397.	7.1	51
139	Presence of tumoural C-reactive protein correlates with progressive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2011, 14, 122-128.	3.9	29
140	Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer. <i>British Journal of Cancer</i> , 2011, 105, 1362-1369.	6.4	26
141	Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 605-614.	4.1	33
142	Molecular alterations in <i>AKT1</i> , <i>AKT2</i> and <i>AKT3</i> detected in breast and prostatic cancer by FISH. <i>Histopathology</i> , 2010, 56, 203-211.	2.9	41
143	Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction. <i>British Journal of Cancer</i> , 2010, 102, 1503-1510.	6.4	12
144	Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression. <i>British Journal of Cancer</i> , 2010, 103, 899-909.	6.4	61

#	ARTICLE	IF	CITATIONS
145	Is there an association with phosphorylation and dephosphorylation of Src kinase at tyrosine 530 and breast cancer patient disease-specific survival. <i>British Journal of Cancer</i> , 2010, 103, 1831-1834.	6.4	10
146	Sphingosine Kinase 1 Induces Tolerance to Human Epidermal Growth Factor Receptor 2 and Prevents Formation of a Migratory Phenotype in Response to Sphingosine 1-Phosphate in Estrogen Receptor-Positive Breast Cancer Cells. <i>Molecular and Cellular Biology</i> , 2010, 30, 3827-3841.	2.3	94
147	Sphingosine 1-Phosphate Receptor 4 Uses HER2 (ERBB2) to Regulate Extracellular Signal Regulated Kinase-1/2 in MDA-MB-453 Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2010, 285, 35957-35966.	3.4	72
148	Is Src a Viable Target for Treating Solid Tumours?. <i>Current Cancer Drug Targets</i> , 2010, 10, 683-694.	1.6	16
149	High Expression of Sphingosine 1-Phosphate Receptors, S1P1 and S1P3, Sphingosine Kinase 1, and Extracellular Signal-Regulated Kinase-1/2 Is Associated with Development of Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Patients. <i>American Journal of Pathology</i> , 2010, 177, 2205-2215.	3.8	156
150	A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth. <i>Cancer Research</i> , 2009, 69, 2305-2313.	0.9	763
151	Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 3540-3549.	7.0	147
152	Is the biology of breast cancer changing? A study of hormone receptor status 1984-1986 and 1996-1997. <i>British Journal of Cancer</i> , 2009, 100, 807-810.	6.4	23
153	Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. <i>British Journal of Cancer</i> , 2009, 100, 680-683.	6.4	93
154	Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2009, 15, 1487-1495.	7.0	71
155	Is Expression or Activation of Src Kinase Associated with Cancer-Specific Survival in ER-, PR- and HER2-Negative Breast Cancer Patients?. <i>American Journal of Pathology</i> , 2009, 175, 1389-1397.	3.8	45
156	Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. <i>Oncogene</i> , 2008, 27, 2978-2988.	5.9	72
157	Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. <i>British Journal of Cancer</i> , 2008, 98, 1094-1101.	6.4	79
158	Is PTEN loss associated with clinical outcome measures in human prostate cancer?. <i>British Journal of Cancer</i> , 2008, 99, 1296-1301.	6.4	123
159	Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer. <i>British Journal of Cancer</i> , 2008, 99, 1769-1774.	6.4	36
160	The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. <i>BJU International</i> , 2008, 102, 756-761.	2.5	49
161	Expression of Tumor Necrosis Factor α Converting Enzyme in Endocrine Cancers. <i>American Journal of Clinical Pathology</i> , 2008, 129, 735-743.	0.7	9
162	An Increase in N-Ras Expression is Associated with Development of Hormone Refractory Prostate Cancer in a Subset of Patients. <i>Disease Markers</i> , 2008, 24, 157-165.	1.3	8

#	ARTICLE	IF	CITATIONS
163	Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. <i>British Journal of Cancer</i> , 2007, 97, 378-383.	6.4	110
164	Bad expression influences time to androgen escape in prostate cancer. <i>BJU International</i> , 2007, 100, 691-696.	2.5	16
165	Editorial Comment on: Increased Expression of Tumor-Associated Trypsin Inhibitor, TATI, in Prostate Cancer and in Androgen-Independent 22Rv1 Cells. <i>European Urology</i> , 2007, 52, 1680-1681.	1.9	0
166	The role of SRC family kinases in prostate cancer. <i>Translational Oncogenomics</i> , 2007, 2, 67-77.	1.7	9
167	Observer variation in immunohistochemical analysis of protein expression, time for a change?. <i>Histopathology</i> , 2006, 48, 787-794.	2.9	214
168	The Role of HER1-HER4 and EGFRvIII in Hormone-Refractory Prostate Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 123-130.	7.0	93
169	The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor. <i>BJU International</i> , 2005, 95, 1320-1326.	2.5	118
170	The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. <i>BJU International</i> , 2005, 95, 1327-1335.	2.5	113
171	The relationship between angiogenesis and cyclooxygenase-2 expression in prostate cancer. <i>BJU International</i> , 2005, 96, 62-66.	2.5	13
172	Raf-1 expression may influence progression to androgen insensitive prostate cancer. <i>Prostate</i> , 2005, 64, 101-107.	2.3	42
173	Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer. <i>Journal of Pathology</i> , 2005, 205, 522-529.	4.5	52
174	Microdissection and Extraction of DNA From Archival Tissue. , 2004, 97, 071-076.		1
175	The role of c-Jun and c-Fos expression in androgen-independent prostate cancer. <i>Journal of Pathology</i> , 2004, 204, 153-158.	4.5	65
176	HER2 and COX2 expression in human prostate cancer. <i>European Journal of Cancer</i> , 2004, 40, 50-55.	2.8	81
177	Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. <i>British Journal of Cancer</i> , 2003, 89, 552-556.	6.4	380
178	Mutation and Polymorphism Detection: A Technical Overview. , 2003, 226, 287-294.		2
179	Detection of Microsatellite Instability and Loss of Heterozygosity Using DNA Extracted from Formalin-Fixed Paraffin-Embedded Tumor Material by Fluorescence-Based Multiplex Microsatellite PCR. , 2003, 226, 301-308.		1
180	Detection of Microsatellite Instability and Loss of Heterozygosity Using DNA Extracted from Formalin-Fixed Paraffin-Embedded Tumor Material by Fluorescence-Based Multiplex Microsatellite PCR. , 2003, , 301-308.		0

#	ARTICLE	IF	CITATIONS
181	Recurrence in Bladder Cancer: A Molecular Dead End?. <i>Current Genomics</i> , 2003, 4, 417-434.	1.6	0
182	Gene amplifications associated with the development of hormone-resistant prostate cancer. <i>Clinical Cancer Research</i> , 2003, 9, 5271-81.	7.0	144
183	Routine Acid Decalcification of Bone Marrow Samples Can Preserve DNA for FISH and CGH Studies in Metastatic Prostate Cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2002, 50, 113-115.	2.5	48
184	14 Role of androgen receptor gene amplification and protein expression in hormone refractory prostate carcinoma. <i>Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas</i> , 2002, , 423-430.	0.0	0
185	The CAG trinucleotide repeat length in the androgen receptor does not predict the early onset of prostate cancer. <i>BJU International</i> , 2002, 90, 573-578.	2.5	16
186	Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. <i>Journal of Pathology</i> , 2002, 196, 380-385.	4.5	35
187	Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. <i>Journal of Pathology</i> , 2002, 198, 237-244.	4.5	83
188	Direct Kinase Assay Screening for Inhibitors of MAP Kinase. , 2001, 39, 583-588.		0
189	Phosphotyrosine Kinase Assays as a Prescreen for Inhibitors of EGFr. , 2001, 39, 577-581.		0
190	Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer. <i>BJU International</i> , 2001, 88, 633-637.	2.5	40
191	Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder. <i>British Journal of Cancer</i> , 2001, 85, 1894-1899.	6.4	21